Curriculum Vitae

Personal information

Karl Bo Anders Lindahl

Work experience

March 2022 – (current position): Quality Assessor, Swedish Medical Products Agency, Uppsala Sweden.

May 2020 – October 2021: Scientific Adviser, Catalent Pharma Solutions, Science & Technology, Södertälje, Sweden.

July 2018 – May 2020: Pharmacokinetics Assessor, Medical Products Agency, Uppsala, Sweden.

October 2015 – July 2018: Biopharmaceutics Strategist, Medical Products Agency, Uppsala, Sweden.

January 2013- October 2015: Acting Scientific Director for Pharmaceutics and Biotechnology, Medical Products Agency. Uppsala, Sweden.

September 2012- January 2013: Biopharmaceutics Strategist, Medical Products Agency, Uppsala, Sweden.

September 2004 – September 2012: Associate Principal Scientist, biopharmaceutics. AstraZeneca R&D, Södertälje Sweden

September 2002 – Sept 2004: Pharmaceutical Assessor, Medical Products Agency, Uppsala Sweden

March 1999 – August 2002: Senior Scientist and Associate Principal Scientist, biopharmaceutics. AstraZeneca R&D, Mölndal, Sweden.

September 1993-March 1999: PhD-student, Uppsala University, Sweden

June 1991 – September 1993 Pharmacist, Apoteksbolaget AB, Malmö, Sweden.

Education and training

September 1993-March 1999: PhD-student, Uppsala University, Sweden. Biopharmaceutics.

August 1990 - March 1991: Diploma work, USCF, San Francisco, USA. Pharmacokinetics

September 1986 - June 1990 Pharmacist (MSc), Uppsala university, Sweden

Additional information

Publications

Efthymios Manolis, Alfredo García-Arieta, **Anders Lindahl**, Evangelos Kotzagiorgis, Jobst Limberg, Øyvind Holte, Paulo Paixao, Carolien Versantvoort, Flora Musuamba Tshinanu, Kevin Blake and Michiel Van Den Heuvel. *Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective*. CPT Pharmacometrics Syst Pharmacol. 2023;00:1–4.

Malin Filler and **Anders Lindahl**. *Regulatory Assessment, European Perspective*, In Oral Drug Delivery for Modified Release Formulations. Edited by Edmund Kostewicz, Maria Vertzoni, Heather Benson and Michael Roberts. John Wiley & Sons, Inc. Hoboken, New Jersey, USA. ISBN: 978-1-119-77269-9, March 2022.

A Lindahl and J Neelissen. *Utilization of Physiologically Based Pharmacokinetics Modeling in the Development of Orally Administered Formulations Intended for Systemic Delivery of Small Molecules. Pharmaceutical Outsourcing, May 2021 (not peer reviewed)*

A Lindahl and J Neelissen. *Physiologically based pharmacokinetics modelling*

in early development of oral drugs. AAPS Newsmagazine, March 2021 (not peer reviewed)

Masoud Jamei, Bertil Abrahamsson, Jonathan Brown, Jan Bevernage, Michael B. Bolger, Tycho Heimbach, Eva Karlsson, Evangelos Kotzagiorgis, **Anders Lindahl**, Mark McAllister, James M. Mullin, Xavier Pepin, Christophe Tistaert, David B. Turner and Filippos Kesisoglou. *Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 155, 55-68.*

B Abrahamsson, M McAllister, P Augustijns, P Zane, J Butler, R Holm, P Langguth, **A Lindahl**, A Müllertz, X Pepin, A Rostami-Hodjegan, E Sjögren, M Berntsson, H Lennernäs. *Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project. European Journal of Pharmaceutics and Biopharmaceutics, 2020,*
152, 236-247.

Sandra Suarez-Sharp, **Anders Lindahl**, Tycho H. Heimbach, Amin Rostami-Hodjegan, Michael B. Bolger, Siladitya Ray Chaudhuri and Bart Hens. *Translational modeling strategies for orally administered drug products: Academic, Industrial and Regulatory Perspectives. Pharm Res 2020, 37, 95.*

Lennernäs H, **Lindahl A**, Van Peer A, Ollier C, Flanagan T, Lionberger R, Nordmark A, Yamashita S, Yu L, Amidon GL, Fischer V, Sjögren E, Zane P, McAllister M, Abrahamsson B. *In Vivo predictive dissolution (IPD) and biopharmaceutical modeling and simulation: future use of modern approaches and methodologies in a regulatory context. Molecular Pharmaceutics 2017 4, 1307-1314.*

Flanagan T, Van Peer A and **Lindahl A**. *Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: Where are we now and what are the gaps? Eur J Pharm Sci. 2016 Aug 25;91:84-90.*

Christer Tannergren, Anders Borde, Cecilia Boreström, Bertil Abrahamsson, **Anders Lindahl.** *Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans. Eur J Pharm Sci. 2014 57, 200-206.*

Christel A.S. Bergström, Sara B.E. Andersson, Jonas H. Fagerberg, Gert Ragnarsson, **Anders Lindahl**. *Is the full potential of the biopharmaceutics classification system reached? Eur J Pharm Sci. 2014 Volume 57, 224–231.*

Erik Sjögren, Bertil Abrahamsson, Patrick Augustijns, Dieter Becker, Michael B. Bolger, Marcus Brewster, Joachim Brouwers, Talia Flanagan, Matthew Harwood, Christian Heinen, Rene Holm, Hans-Paul Juretschke, Marlies Kubbinga, **Anders Lindahl**, Viera Lukacova, Uwe Münster, Sibylle Neuhoff, May Nguyen, Achiel van Peer, Christos Reppas, Amin Rostami, Christer Tannergren, Werner Weitschies, Clive Wilson, Patricia Zane, Hans Lennernäs, Peter Langguth. *In vivo methods for drug absorption and API/formulations studies. Eur J Pharm Sci. 2014 57:99-151.*

Lennernäs, H., Aarons, L., Augustijns, P., Beato, S., Bolger, M., Box, K., Brewster, M.,
Butler, J., Dressman, J., Holm, R., Julia Frank K., Kendall R., Langguth, P.,

Sydor, J., **Lindahl, A.**, McAllister, M., Muenster, U., Müllertz, A., Ojala, K, Pepin, X., Reppas, C., Rostami-Hodjegan, A., Verwei, M., Weitschies,W., Wilson, C., Karlsson, C., Abrahamsson, B., *Oral biopharmaceutics tools – time for a new initiative – an introduction to the IMI project OrBiTo, Eur J Pharm Sci. 2014, 57, 292-299.*

Sigfridsson K. Nordmark A. Theilig S. **Lindahl A**. *A formulation comparison between micro- and nonosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Development and Industrial Pharmacy. 2011, 37(2), 185-192.*

Lindahl A. Sjöberg A. Bredberg U. Toreson H. Ungell AL. Lennernäs H. *Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Molecular Pharmaceutics. 1(5):347-56, 2004.*

Lindahl A. Frid S. Ungell AL. Lennernäs H. *No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat. AAPS Pharmsci. 2(3):E26, 2000.*

Bonlokke L. Hovgaard L. Kristensen HG. Knutson L. **Lindahl A**. Lennernäs H. *A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. European Journal of Pharmaceutical Sciences. 8(1):19-27, 1999.*

Lindahl Anders. *Intestinal transport and hepatic extraction of fluvastatin in humans and rats. Acta Universitatis Upsaliensis Thesis, 1999*

Lindahl A. Persson B. Ungell AL. Lennernäs H. *Surface activity and concentration dependent intestinal permeability in the rat. Pharmaceutical Research. 16(1):97-102, 1999.*

Lindahl A. Sandström R. Ungell AL. Lennernäs H. *Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. Journal of Pharmacy & Pharmacology. 50(7):737-44, 1998.*

Lindahl A. Krondahl E. Gruden AC. Ungell AL. Lennernäs H. *Is the jejunal permeability in rats age-dependent? Pharmaceutical Research. 14(9):1278-81,1997.*

Fagerholm U. **Lindahl A**. Lennernäs H. *Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. Journal of Pharmacy & Pharmacology. 49(7):687-90, 1997.*

Lindahl A. Ungell AL. Knutson L. Lennernäs H. *Characterization of fluids from the stomach and proximal jejunum in men and women. Pharmaceutical Research. 14(4):497-502, 1997.*

Lindahl A. Sandström R. Ungell AL. Abrahamsson B. Knutson TW. Knutson L. Lennernäs H. *Jejunal permeability and hepatic extraction of fluvastatin in humans. Clinical Pharmacology & Therapeutics. 60(5):493-503, 1996.*

Projects

Memberships

Other Relevant Information